Witte F, Ständer S, Zeidler C
Sektion Pruritusmedizin, Kompetenzzentrum Chronischer Pruritus (KCP), Klinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland.
Dermatologie (Heidelb). 2024 Aug;75(8):623-628. doi: 10.1007/s00105-024-05375-y. Epub 2024 Jun 13.
Despite the high burden in patients with chronic prurigo (CPG), the first and so far only approved systemic therapy for this disease, dupilumab, has only been available since 2022. Therefore, treatment is mostly based on expert recommendations for off-label therapies. We aim to provide an overview of current therapies and possible future therapeutic drugs for CPG patients, which are currently in clinical trials.
For this review, a systematic literature and clinical trial search was conducted via PubMed and Clinical Trials using the terms "chronic prurigo", "chronic nodular prurigo", "prurigo nodularis" and "therapy".
Multiple new therapeutic agents are currently under investigation in clinical trials, providing promising results for future treatment options. Moreover, an annotated checklist was developed recently to improve therapeutic decision-making in daily clinical practice with CPG patients.
尽管慢性痒疹（CPG）患者负担沉重，但针对该疾病的首个且迄今唯一获批的全身治疗药物度普利尤单抗自2022年才开始可用。因此，治疗大多基于专家对非标签疗法的建议。我们旨在概述目前针对CPG患者的疗法以及目前正在临床试验中的可能的未来治疗药物。
对于本综述，通过PubMed和临床试验数据库，使用“慢性痒疹”“慢性结节性痒疹”“结节性痒疹”和“治疗”等术语进行了系统的文献和临床试验检索。
目前多种新治疗药物正在临床试验中进行研究，为未来的治疗选择提供了有前景的结果。此外，最近制定了一份注释清单，以改善CPG患者日常临床实践中的治疗决策。
